Pacer S&P 500 Quality FCF High Dividend ETF (QFHD) has seen unusual trading volume, which is 29× higher than its average daily volume.
Among its top holdings, Pfizer Inc., a 2.0% weight in the fund, updated investors on a new Phase 3 trial testing its experimental cancer drug PF-08634404 plus chemotherapy against Merck’s pembrolizumab in advanced endometrial cancer, with the study now in startup and not yet recruiting. Devon Energy, a 1.9% position, was in focus as multiple analysts reiterated or initiated coverage: RBC Capital maintained a Hold rating with a $59 price target, Evercore ISI started coverage with a Hold and $54 target, and Wells Fargo issued a Buy rating with a $68 target, while the broader consensus points to a Strong Buy with notable upside potential.